替马洛尔-多唑胺固定联合治疗新诊断开角型青光眼的疗效和安全性:每日3次vs每日2次。

IF 2.4 Journal of Drug Assessment Pub Date : 2021-08-23 eCollection Date: 2021-01-01 DOI:10.1080/21556660.2021.1967642
Mohammad Pakravan, Afsaneh Naderi Beni, Shahin Yazdani, Hamed Esfandiari, Shahram Mirshojaee
{"title":"替马洛尔-多唑胺固定联合治疗新诊断开角型青光眼的疗效和安全性:每日3次vs每日2次。","authors":"Mohammad Pakravan,&nbsp;Afsaneh Naderi Beni,&nbsp;Shahin Yazdani,&nbsp;Hamed Esfandiari,&nbsp;Shahram Mirshojaee","doi":"10.1080/21556660.2021.1967642","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination(Cosopt) in newly diagnosed primary open-angle glaucoma (POAG) patients.</p><p><strong>Methods: </strong>In this prospective, interventional case series, newly POAG patients were included. Patients were started on Cosopt twice a day (BID) for one month and then switched to three times a day (TDS) for an additional month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP), and 24-h heart rate (HR) measurements at baseline, month 1(BID), and month 2(TDS). Throughout the study, all adverse events were monitored by the investigators.</p><p><strong>Results: </strong>In 31 POAG patients that completed the study, the mean baseline IOP was 23.1 ± 3.15 mmHg. IOP was decreased significantly 16.5 ± 2.21 at one month (<i>p</i> < .0001) and 13.9 ± 2.23 mmHg at 1 and 2 months follow up (<i>p</i> < .0001). IOP was significantly lower in month 2 compared to month 1 (<i>p</i> = .0004). While Cosopt BID significantly reduced the mean 24-h systolic BP and mean 24-h HR from baseline (<i>p</i> < .0001), the mean 24-h systolic BP and HR remained unchanged with Cosopt TDS compared to BID (<i>p</i> = .62).</p><p><strong>Conclusions: </strong>Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.</p>","PeriodicalId":15631,"journal":{"name":"Journal of Drug Assessment","volume":"10 1","pages":"91-96"},"PeriodicalIF":2.4000,"publicationDate":"2021-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/bd/IJDA_10_1967642.PMC8386705.pdf","citationCount":"2","resultStr":"{\"title\":\"Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.\",\"authors\":\"Mohammad Pakravan,&nbsp;Afsaneh Naderi Beni,&nbsp;Shahin Yazdani,&nbsp;Hamed Esfandiari,&nbsp;Shahram Mirshojaee\",\"doi\":\"10.1080/21556660.2021.1967642\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>This study aimed to compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination(Cosopt) in newly diagnosed primary open-angle glaucoma (POAG) patients.</p><p><strong>Methods: </strong>In this prospective, interventional case series, newly POAG patients were included. Patients were started on Cosopt twice a day (BID) for one month and then switched to three times a day (TDS) for an additional month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP), and 24-h heart rate (HR) measurements at baseline, month 1(BID), and month 2(TDS). Throughout the study, all adverse events were monitored by the investigators.</p><p><strong>Results: </strong>In 31 POAG patients that completed the study, the mean baseline IOP was 23.1 ± 3.15 mmHg. IOP was decreased significantly 16.5 ± 2.21 at one month (<i>p</i> < .0001) and 13.9 ± 2.23 mmHg at 1 and 2 months follow up (<i>p</i> < .0001). IOP was significantly lower in month 2 compared to month 1 (<i>p</i> = .0004). While Cosopt BID significantly reduced the mean 24-h systolic BP and mean 24-h HR from baseline (<i>p</i> < .0001), the mean 24-h systolic BP and HR remained unchanged with Cosopt TDS compared to BID (<i>p</i> = .62).</p><p><strong>Conclusions: </strong>Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.</p>\",\"PeriodicalId\":15631,\"journal\":{\"name\":\"Journal of Drug Assessment\",\"volume\":\"10 1\",\"pages\":\"91-96\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2021-08-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/bd/IJDA_10_1967642.PMC8386705.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Drug Assessment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21556660.2021.1967642\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drug Assessment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21556660.2021.1967642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

目的:比较多唑胺/替洛尔固定联合治疗新发原发性开角型青光眼(POAG)的疗效和安全性。方法:在这个前瞻性的介入病例系列中,纳入了新发POAG患者。患者开始服用coopt,每天两次(BID),持续一个月,然后改为每天三次(TDS),再持续一个月。患者在基线、第1个月(BID)和第2个月(TDS)时接受全面眼科检查、每日眼压(IOP)、血压(BP)和24小时心率(HR)测量。在整个研究过程中,研究人员对所有不良事件进行了监测。结果:31例POAG患者完成研究,平均基线IOP为23.1±3.15 mmHg。1个月时IOP显著降低(16.5±2.21)(p p p = 0.0004)。而coopt BID较基线显著降低了平均24小时收缩压和平均24小时HR (p p = 0.62)。结论:在安全性相当的POAG患者中,coopt TDS比coopt BID具有更好的降低眼压的效果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of timolol-dorzolamide fixed-combination three times a day versus two times a day in newly diagnosed open-angle glaucoma.

Objective: This study aimed to compare the therapeutic efficacy and safety of dorzolamide/timolol fixed-combination(Cosopt) in newly diagnosed primary open-angle glaucoma (POAG) patients.

Methods: In this prospective, interventional case series, newly POAG patients were included. Patients were started on Cosopt twice a day (BID) for one month and then switched to three times a day (TDS) for an additional month. Patients underwent comprehensive ophthalmic examination, diurnal intraocular pressure (IOP), blood pressure (BP), and 24-h heart rate (HR) measurements at baseline, month 1(BID), and month 2(TDS). Throughout the study, all adverse events were monitored by the investigators.

Results: In 31 POAG patients that completed the study, the mean baseline IOP was 23.1 ± 3.15 mmHg. IOP was decreased significantly 16.5 ± 2.21 at one month (p < .0001) and 13.9 ± 2.23 mmHg at 1 and 2 months follow up (p < .0001). IOP was significantly lower in month 2 compared to month 1 (p = .0004). While Cosopt BID significantly reduced the mean 24-h systolic BP and mean 24-h HR from baseline (p < .0001), the mean 24-h systolic BP and HR remained unchanged with Cosopt TDS compared to BID (p = .62).

Conclusions: Cosopt TDS has a superior IOP-lowering effect than Cosopt BID in POAG patients with comparable safety profiles.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Drug Assessment
Journal of Drug Assessment PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
0
审稿时长
8 weeks
期刊最新文献
Treatment and comorbidity burden among people living with HIV: a review of systematic literature reviews. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses. Real world evidence study on treatment patterns and health resource utilization in patients with HR+/HER2- locally advanced or metastatic breast cancer in Korea. A review of the risks of long-term consequences associated with components of the CHOP chemotherapy regimen. Real-world experience of ocrelizumab in multiple sclerosis in an Arab population.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1